GuruFocus

03 Jun 2026, 05:00 UTC · 3h ago

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

Read original · https://www.gurufocus.com/news/8897641/johnson-johnson-presents-new-data-further-reinforcing-the-role-of-nipocalimab-in-lowering-the-autoantibodies-driving-sjgrens-disease

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
Johnson & Johnson presented new data reinforcing the efficacy of nipocalimab in reducing autoantibodies associated with Sjögren's disease. — Positive clinical data for a potential new drug treatment increases the likelihood of regulatory approval and future revenue streams.
+0.60

Ticker attribution

Model heads

Sentiment in this article

JNJ+0.60
Positive new data on nipocalimab for the treatment of Sjögren's disease.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

Browse live screenings

Impact vectors

6 related stories

GlobeNewsWire
3h ago
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- pharmaceuticals
- sjogrens disease
Read

Johnson & Johnson presents new data further reinforcing the role of n… · News Impact Screener

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released